We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Moderna (MRNA - Free Report) closed at $155.56, marking a +0.2% move from the previous day. This move outpaced the S&P 500's daily loss of 0.41%. Meanwhile, the Dow lost 0.11%, and the Nasdaq, a tech-heavy index, lost 4.08%.
Coming into today, shares of the biotechnology company had gained 2.62% in the past month. In that same time, the Medical sector gained 6.85%, while the S&P 500 gained 6.51%.
Wall Street will be looking for positivity from Moderna as it approaches its next earnings report date. On that day, Moderna is projected to report earnings of -$1.73 per share, which would represent a year-over-year decline of 120.16%. Meanwhile, our latest consensus estimate is calling for revenue of $1.19 billion, down 80.42% from the prior-year quarter.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of -$2.43 per share and revenue of $7.28 billion. These results would represent year-over-year changes of -112.08% and -62.22%, respectively.
It is also important to note the recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 7.16% lower. Moderna is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Gains As Market Dips: What You Should Know
In the latest trading session, Moderna (MRNA - Free Report) closed at $155.56, marking a +0.2% move from the previous day. This move outpaced the S&P 500's daily loss of 0.41%. Meanwhile, the Dow lost 0.11%, and the Nasdaq, a tech-heavy index, lost 4.08%.
Coming into today, shares of the biotechnology company had gained 2.62% in the past month. In that same time, the Medical sector gained 6.85%, while the S&P 500 gained 6.51%.
Wall Street will be looking for positivity from Moderna as it approaches its next earnings report date. On that day, Moderna is projected to report earnings of -$1.73 per share, which would represent a year-over-year decline of 120.16%. Meanwhile, our latest consensus estimate is calling for revenue of $1.19 billion, down 80.42% from the prior-year quarter.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of -$2.43 per share and revenue of $7.28 billion. These results would represent year-over-year changes of -112.08% and -62.22%, respectively.
It is also important to note the recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 7.16% lower. Moderna is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.